Greenlight's Einhorn Highlights Lanxess as Potential Tariff Beneficiary

Lanxess was founded in 2004 after Bayer AG spun off its chemicals division. The company has since focused on shifting away from cyclical commodity businesses to more stable and higher-margin specialty chemicals. While this transformation faced initial setbacks, Einhorn believes Lanxess is now on a successful path to realizing the benefits of these changes.

Einhorn highlighted that Lanxess, as a domestic manufacturer with almost 30% of its capacity in the U.S., could benefit from tariffs by raising prices. In certain sectors, such as parts of its advanced industrial intermediate business unit, Lanxess is the only remaining U.S. producer, competing with Chinese firms. This unique position makes it particularly attractive as a tariff beneficiary.

Lanxess has strategically shifted to specialty chemicals and could benefit from tariffs, potentially leading to market outperformance.

The company has significant manufacturing capacity in the U.S. and is the sole remaining U.S. producer in some sectors, allowing it to raise prices in response to tariffs.

Do you think Lanxess will capitalize on its strategic advantages and tariff benefits? Share your thoughts below!

Share this article with others who need to stay ahead of this trend!